MediPharm Labs Corp.
LABS.TO
TSX
| Weiss Ratings | LABS.TO - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | LABS.TO - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Good | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | LABS.TO - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -0.05 | |||
| Price History | LABS.TO - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.00% | |||
| 30-Day Total Return | 15.38% | |||
| 60-Day Total Return | 15.38% | |||
| 90-Day Total Return | 7.14% | |||
| Year to Date Total Return | 15.38% | |||
| 1-Year Total Return | 15.38% | |||
| 2-Year Total Return | 7.14% | |||
| 3-Year Total Return | -48.28% | |||
| 5-Year Total Return | -95.92% | |||
| 52-Week High % Change | -30.00% | |||
| 52-Week Low % Change | 16.67% | |||
| Price | LABS.TO - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.10 | |||
| 52-Week Low Price | $0.06 | |||
| 52-Week Low Price (Date) | Sep 06, 2024 | |||
| 52-Week High Price (Date) | Mar 26, 2024 | |||
| Valuation | LABS.TO - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 20.00M | |||
| Enterprise Value | 11.12M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.02 | |||
| Earnings Per Share Growth | -41.06% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 1.00 | |||
| Price/Book (Q) | 0.86 | |||
| Enterprise Value/Revenue (TTM) | 0.39 | |||
| Price | $0.08 | |||
| Enterprise Value/EBITDA (TTM) | -5.85 | |||
| Enterprise Value/EBIT | -2.87 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | LABS.TO - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 411.07M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | LABS.TO - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 705 719 7425 | |||
| Address | 151 John Street Barrie, ON L4N 2L1 | |||
| Website | www.medipharmlabs.com | |||
| Country | Canada | |||
| Year Founded | 2015 | |||
| Profitability | LABS.TO - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -13.50% | |||
| Profit Margin | -30.58% | |||
| Management Effectiveness | LABS.TO - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -5.29% | |||
| Return on Equity | -- | |||
| Income Statement | LABS.TO - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 28.71M | |||
| Total Revenue (TTM) | 28.71M | |||
| Revenue Per Share | $0.07 | |||
| Gross Profit (TTM) | 10.74M | |||
| EBITDA (TTM) | -1.90M | |||
| EBIT (TTM) | -3.88M | |||
| Net Income (TTM) | -8.78M | |||
| Net Income Avl. to Common (TTM) | -8.78M | |||
| Total Revenue Growth (Q YOY) | 13.29% | |||
| Earnings Growth (Q YOY) | 36.96% | |||
| EPS Diluted (TTM) | -0.02 | |||
| EPS Diluted Growth (Q YOY) | 39.51% | |||
| Balance Sheet | LABS.TO - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 9.94M | |||
| Cash Per Share (Q) | $0.02 | |||
| Total Current Assets (Q) | 25.59M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 33.35M | |||
| Current Ratio (Q) | 3.213 | |||
| Book Value Per Share (Q) | $0.08 | |||
| Total Assets (Q) | 41.34M | |||
| Total Current Liabilities (Q) | 7.96M | |||
| Total Debt (Q) | 484.10K | |||
| Total Liabilities (Q) | 7.99M | |||
| Total Common Equity (Q) | 33.35M | |||
| Cash Flow | LABS.TO - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 3.51M | |||
| Cash from Financing (TTM) | -1.35M | |||
| Net Change in Cash (TTM) | 106.60K | |||
| Levered Free Cash Flow (TTM) | 5.26M | |||
| Cash from Operations (TTM) | -1.71M | |||
